Quantcast
Channel: Endpoints News
Browsing all 3599 articles
Browse latest View live

Boehringer Ingelheim’s late-stage data for lung disease candidate underwhelm...

Boehringer Ingelheim claimed two Phase 3 wins for its PDE4 inhibitor in fibrotic lung diseases, but some Wall Street analysts said the candidate’s “modest” efficacy and limited combination potential...

View Article


Stelara biosimilars look to gain traction, helped by recent lessons from Humira

AbbVie's defense of its megablockbuster Humira may go down in the history books as the poster child for blocking biosimilar competition, but the launch of six Stelara biosimilars this year shows how...

View Article


Why Regeneron is buying 23andMe

Regeneron is doubling down on its genetics research ambitions by agreeing to buy most of 23andMe’s business out of bankruptcy. Regeneron is best known for developing blockbuster drugs like Dupixent and...

View Article

Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks...

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with the Murdoch Children's Research Institute in Australia. The California...

View Article

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Pfizer is set to enter the heated VEGF bispecific arena. Much like its peers, the New York drug giant is doing so by going to China in the battle for one of oncology's hottest classes ...

View Article


Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Biotech execs don’t quite know what to make of the new FDA chief. There’s been plenty of head-shaking about the controversial provocateur he named to run CBER. Robert F. Kennedy Jr. at ...

View Article

At-home screening startup Reperio Health raises $14M

Telehealth is becoming more comprehensive than a quick online visit. Portland, OR-based Reperio Health got its start in 2020 selling at-home testing kits for employers and health plans, but this year...

View Article

Optura raises $6.5M to help evaluate healthcare AI programs

Healthcare is figuring out what AI to use in a crowded market. Optura says it can help tell you if what you are trying is worth it. The startup, offering a system designed to analyze ...

View Article


Weight loss startup Calibrate replaces CEO in leadership shakeup 

Calibrate has replaced its CEO and made several other executive changes, Endpoints News has learned, the latest leadership reset at the once high-flying weight loss company. Rob Rebak, a veteran CEO of...

View Article


Trump administration reveals 'most favored nation' drug price country targets

The Department of Health and Human Services provided the first details for how it plans to tie US drug prices to rates paid in similarly developed countries as part of President Donald Trump’s most...

View Article

SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff

Plus, news about Beckley Psytech, Regenxbio, Blueprint Medicines, VantAI, NovelMed and Bayer: 💰 SV Health closes second dementia fund: The London-based biotech investment firm closed its second...

View Article

Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with...

Tourmaline Bio's experimental drug for atherosclerotic heart disease reduced markers of inflammation in the blood in a mid-stage study. The company must now show the drug cuts key events such as heart...

View Article

Future Covid vaccine approvals may narrow to older adults, high-risk people

FDA chief Marty Makary and new CBER Director Vinay Prasad said that future Covid-19 vaccine approvals will focus on adults over 65 and high-risk people 6 months to 64 years old, aligning US policy with...

View Article


RFK Jr. spars with senators over HHS budget and research cuts

Senate Democrats grilled HHS Secretary Robert F. Kennedy Jr. on Tuesday over gaps in his budget and funding cuts that have halted or eliminated key clinical research. For the most part, Kennedy pleaded...

View Article

CRISPR Therapeutics partners with siRNA company, showing that gene editing...

The gene editing company CRISPR Therapeutics struck a deal worth $95 million upfront with China-based biotech Sirius Therapeutics to jointly develop its experimental gene-silencing siRNA drug for blood...

View Article


Updated: FDA adcomm splits votes on Genentech and J&J cancer drugs

The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US patient population for a Columvi label expansion. In the afternoon session,...

View Article

Vinay Prasad makes first major imprint on FDA with new vaccine policy

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for approving future Covid-19 vaccines that he feels will counteract existing “dogma.”...

View Article


UK biotech Juvenescence targets $150M+ for 'healthy lifespan' drug candidates

The "healthy lifespan" space is attracting more dollars. Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic. The drug development startup,...

View Article

Reproductive health biotech ReproNovo closes $65M Series A

A Swiss biotech has secured $65 million to launch a trio of mid-stage trials for two reproductive health drugs. ReproNovo announced the close of its Series A round on Wednesday. CEO Jean Marie Duvall...

View Article

Altos Labs buys anti-aging startup Dorian Therapeutics

Altos Labs, the massive but still relatively secretive $3 billion biotech, has forged a small acquisition of a startup seeking to reverse aging. Altos, led by industry stalwarts Hal Barron and Hans ...

View Article
Browsing all 3599 articles
Browse latest View live